BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35109829)

  • 1. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden.
    Balabanova Y; Farahmand B; Stattin P; Garmo H; Brobert G
    BMC Urol; 2022 Feb; 22(1):15. PubMed ID: 35109829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
    Kirkilesis GI; Kakkos SK; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden.
    Balabanova Y; Farahmand B; Garmo H; Stattin P; Brobert G
    BMJ Open; 2022 May; 12(5):e055485. PubMed ID: 35606159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
    Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
    Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Venous Thromboembolism and Benefits and Risks of Thromboprophylaxis After Cardiac Surgery: A Systematic Review and Meta-Analysis.
    Ho KM; Bham E; Pavey W
    J Am Heart Assoc; 2015 Oct; 4(10):e002652. PubMed ID: 26504150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
    Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
    JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of bleeding and recurrence in isolated distal deep vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital.
    Jørgensen CT; Tavoly M; Førsund E; Pettersen HH; Tjønnfjord E; Ghanima W; Brækkan SK
    J Thromb Haemost; 2023 Oct; 21(10):2824-2832. PubMed ID: 37394122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
    Kearon C; Akl EA
    Blood; 2014 Mar; 123(12):1794-801. PubMed ID: 24497538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
    Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
    PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
    Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
    J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.
    Turpie AGG; Farjat AE; Haas S; Ageno W; Weitz JI; Goldhaber SZ; Goto S; Angchaisuksiri P; Kayani G; Lopes RD; Chiang CE; Gibbs H; Tse E; Verhamme P; Ten Cate H; Muntaner J; Schellong S; Bounameaux H; Prandoni P; Maheshwari U; Kakkar AK;
    Thromb Res; 2023 Feb; 222():31-39. PubMed ID: 36565677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.
    Lecumberri R; Alfonso A; Jiménez D; Fernández Capitán C; Prandoni P; Wells PS; Vidal G; Barillari G; Monreal M;
    Thromb Haemost; 2013 Oct; 110(4):834-43. PubMed ID: 23846721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].
    Couturaud F; Pernod G; Pison C; Mismetti P; Sanchez O; Meyer G; Parent F; Girard P; Simonneau G; Drouet L; Gueret P; Jego P; Delaval P; Duhamel E; Gruel Y; Delahousse B; Regina S; Pottier P; Connaud J; Lecomte F; Provost K; Vilmans N; Gosset X; Bura-Rivière A; Meach G; Lacut K; Bosson JL; Guillot K; Mottier D; Leroyer C
    Rev Mal Respir; 2008 Sep; 25(7):885-93. PubMed ID: 18946418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.